From GlobeNewswire: 2025-04-23 08:00:00

Inspira Technologies announced a major milestone in in-vivo testing of its VORTX technology, achieving over 99% gas exchange target. This innovative technology aims to transform acute respiratory care by providing a non-invasive alternative to mechanical ventilation, reducing blood trauma. The successful trial was conducted at Israel’s Institute of Animal Research, confirming scalability and proof-of-concept. CEO Dagi Ben-Noon expressed pride in this achievement and highlighted the company’s commitment to advancing life-support technology. Inspira plans to further develop the VORTX technology and provide updates in the near future.

Inspira Technologies specializes in developing respiratory support and diagnostic technologies, with flagship products like the INSPIRA ART500 system and HYLA blood sensor. These products aim to revolutionize critical care by stabilizing oxygen levels without mechanical ventilation. The company’s pipeline products are currently in development and have not yet received regulatory approval.

For more information on Inspira Technologies, visit their corporate website.



Read more at GlobeNewswire: Inspira Achieves above 99% Gas Exchange Efficiency in